Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab
Semaglutide Nears Market For Obesity
Executive Summary
With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.
You may also be interested in...
Novo Nordisk Pays $1.80bn To Buy Emisphere
The Danish major will develop the US firm's technology and use it on current and future pipeline assets with the aim of making more biologics orally available.
Novo Nordisk Looks To Increase Its Global GLP-1 Lead
Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.
Novo Nordisk Fortifies Cardio-Renal Efforts With Corvidia Buy
Novo Nordisk is paying $725m to acquire the VC-backed US biotech, Corvidia Therapeutics and its promising Phase II candidate, ziltivekimab, for chronic kidney disease, but further payments could total more than $2bn.
Need a specific report? 1000+ reports available
Buy Reports